PIK3CA and neoplasm: In conclusion, our study demonstrates that ≥20% tumor cellularity is required to identify T790M mutation as the cause of TKI resistance, and to detect HER2/BRAF/PIK3CA mutations in biopsy samples using the amplification‐based NGS testing.